Minerva Neurosciences, INC 10-Q quarterly reports

Minerva Neurosciences reports progress on its Phase 3 C19 trial for roluperidone, but faces significant financial challenges with a substantial accumulated deficit and ongoing operational losses.

Minerva Neurosciences reports significant increase in R&D and G&A expenses for Q1 2026, driven by the C19 trial initiation and a settlement agreement, while cash reserves remain a key focus for ongoing operations.

Minerva Neurosciences reported a net loss for Q3 2025 and secured up to $200 million in a private placement to fund a new confirmatory Phase 3 trial for roluperidone after an FDA Complete Response Letter.

Minerva Neurosciences reports reduced losses but faces a new confirmatory clinical trial requirement for its lead drug roluperidone and is exploring strategic alternatives due to its cash position.

Minerva Neurosciences announces its Q1 2025 financial results, highlighting a decrease in research and development expenses and providing an update on the regulatory status of roluperidone following a Complete Response Letter from the FDA.

Minerva Neurosciences reported a net income of $5.7 million for the nine months ended September 30, 2024, primarily due to a significant gain from a royalty liability adjustment, despite ongoing operating losses.

Minerva Neurosciences reported a net loss of $16.8 million for the first half of 2024 and is navigating challenges with its lead drug candidate's regulatory approval.

Minerva Neurosciences reported a net loss of $8.6 million for the first quarter of 2024 and received a Complete Response Letter from the FDA regarding its New Drug Application for roluperidone.